CD274 and head and neck squamous cell carcinoma: Therefore, a phase-IIb randomised study has been launched to enrol 96 patients with PDL-1 negative HNSCC of the oral cavity/oropharynx treated with standard systemic treatment (cetuximab + platinum-based agent + 5-fluorouracil) or ECT with bleomycin and assess whether local therapy improves response compared with systemic treatment alone [209].